Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer

Table 2 Correlations between the pre-treatment lymphocyte to monocyte ratio and clinicopathological factors

	Pre-treatment LMR
	High	Low	P value
Performance status
0	62	34
1, 2	4	4	0.459
Location of primary tumor
Colon	39	21
Rectum	27	17	0.837
Detection of unresectable tumor
Synchronous	39	23
Metachronous	27	15	1.000
Resection of primary tumor
No	8	8
Yes	58	30	0.264
Histological type
Well, moderately	51	30
Poorly, mucinous	10	4	0.764
KRAS
Wild type	15	10
Mutant type	15	10	1.000
Peritoneal dissemination
Negative	53	32
Positive	13	6	0.793
Number of organs affected by metastasis
One organ	39	19
More than one organ	27	19	0.416
Pre-treatment CEA (ng/mL)
≤ 5	10	3
> 5	54	35	0.362
Average relative dose intensity (%)
Median (range)	100 (60.0-100)	96.2 (50.0-100)	0.697
Molecular targeted therapy
No	15	13
Yes	51	25	0.253
Pre-treatment NLR
< 2.8	48	5
≥ 2.8	18	33	< 0.001

CEA: Carcinoembryonic antigen; LMR: Lymphocyte to monocyte ratio; NLR: Neutrophil to lymphocyte ratio.